Literature DB >> 21238460

Constraining enzyme conformational change by an antibody leads to hyperbolic inhibition.

David Oyen1, Vasundara Srinivasan, Jan Steyaert, John N Barlow.   

Abstract

Although it has been known for many years that antibodies display properties characteristic of allosteric effectors, the molecular mechanisms responsible for these effects remain poorly understood. Here, we describe a single-domain antibody fragment (nanobody) that modulates protein function by constraining conformational change in the enzyme dihydrofolate reductase (DHFR). Nanobody 216 (Nb216) behaves as a potent allosteric inhibitor of DHFR, giving rise to mixed hyperbolic inhibition kinetics. The crystal structure of Nb216 in complex with DHFR reveals that the nanobody binds adjacent to the active site. Half of the epitope consists of residues from the flexible Met20 loop. This loop, which ordinarily oscillates between occluded and closed conformations during catalysis, assumes the occluded conformation in the Nb216-bound state. Using stopped flow, we show that Nb216 inhibits DHFR by stabilising the occluded Met20 loop conformation. Surprisingly, kinetic data indicate that the Met20 loop retains sufficient conformational flexibility in the Nb216-bound state to allow slow substrate turnover to occur.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21238460     DOI: 10.1016/j.jmb.2011.01.017

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  15 in total

Review 1.  Antibody-enabled small-molecule drug discovery.

Authors:  Alastair D G Lawson
Journal:  Nat Rev Drug Discov       Date:  2012-06-29       Impact factor: 84.694

Review 2.  Distinct antibody species: structural differences creating therapeutic opportunities.

Authors:  Serge Muyldermans; Vaughn V Smider
Journal:  Curr Opin Immunol       Date:  2016-02-27       Impact factor: 7.486

3.  Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies.

Authors:  Dean P Staus; Laura M Wingler; Ryan T Strachan; Soren G F Rasmussen; Els Pardon; Seungkirl Ahn; Jan Steyaert; Brian K Kobilka; Robert J Lefkowitz
Journal:  Mol Pharmacol       Date:  2013-12-06       Impact factor: 4.436

4.  Nanobody-based binding assay for the discovery of potent inhibitors of CFTR inhibitory factor (Cif).

Authors:  Natalia Vasylieva; Seiya Kitamura; Jiexian Dong; Bogdan Barnych; Kelli L Hvorecny; Dean R Madden; Shirley J Gee; Dennis W Wolan; Christophe Morisseau; Bruce D Hammock
Journal:  Anal Chim Acta       Date:  2019-01-09       Impact factor: 6.558

Review 5.  Biotechnological applications of recombinant single-domain antibody fragments.

Authors:  Ario de Marco
Journal:  Microb Cell Fact       Date:  2011-06-09       Impact factor: 5.328

6.  A Nanobody Against Cytotoxic T-Lymphocyte Associated Antigen-4 Increases the Anti-Tumor Effects of Specific CD8+ T Cells.

Authors:  Zhuoran Tang; Fengzhen Mo; Aiqun Liu; Siliang Duan; Xiaomei Yang; Liu Liang; Xiaoqiong Hou; Shihua Yin; Xiaobing Jiang; Natalia Vasylieva; Jiexian Dong; Bogdan Barnych; Bruce D Hammock; Xiaoling Lu
Journal:  J Biomed Nanotechnol       Date:  2019-11-01       Impact factor: 3.641

7.  Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.

Authors:  Stevan Shaw; Tim Bourne; Chris Meier; Bruce Carrington; Rich Gelinas; Alistair Henry; Andrew Popplewell; Ralph Adams; Terry Baker; Steve Rapecki; Diane Marshall; Adrian Moore; Helen Neale; Alastair Lawson
Journal:  MAbs       Date:  2014-04-02       Impact factor: 5.857

8.  Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of action.

Authors:  Rachel L Palte; Veronica Juan; Yacob Gomez-Llorente; Marc Andre Bailly; Kalyan Chakravarthy; Xun Chen; Daniel Cipriano; Laurence Fayadat-Dilman; Symon Gathiaka; Heiko Greb; Brian Hall; Mas Handa; Mark Hsieh; Esther Kofman; Heping Lin; J Richard Miller; Nhung Nguyen; Jennifer O'Neil; Hussam Shaheen; Eric Sterner; Corey Strickland; Angie Sun; Shane Taremi; Giovanna Scapin
Journal:  Commun Biol       Date:  2021-07-29

9.  Structure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodies.

Authors:  Apirat Chaikuad; Tracy Keates; Cécile Vincke; Melanie Kaufholz; Michael Zenn; Bastian Zimmermann; Carlos Gutiérrez; Rong-Guang Zhang; Catherine Hatzos-Skintges; Andrzej Joachimiak; Serge Muyldermans; Friedrich W Herberg; Stefan Knapp; Susanne Müller
Journal:  Biochem J       Date:  2014-04-01       Impact factor: 3.857

10.  A New Nanobody-Based Biosensor to Study Endogenous PARP1 In Vitro and in Live Human Cells.

Authors:  Andrea Buchfellner; Larisa Yurlova; Stefan Nüske; Armin M Scholz; Jacqueline Bogner; Benjamin Ruf; Kourosh Zolghadr; Sophie E Drexler; Guido A Drexler; Stefanie Girst; Christoph Greubel; Judith Reindl; Christian Siebenwirth; Tina Romer; Anna A Friedl; Ulrich Rothbauer
Journal:  PLoS One       Date:  2016-03-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.